Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Fosun to Bid in $2 Billion Auction for Novartis' US Generic Drug Assets

publication date: May 14, 2018

Fosun Pharma is one of the finalists in a $2 billion bidding war to acquire part of Novartis' US portfolio of generic drugs. Novartis is auctioning off US rights to lower-margined members of its Sandoz generic portfolio while it keeps the more profitable generics. India's Aurobindo, US-based Apollo Global Management and CVC Capital Partners, a Europe-Asia PE firm, have also been asked to submit final offers. Novartis' dermatology assets are included in the package. More details....

Stock Symbols: (SHA: 600196; HK: 02196) (NYSE: NVS)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.